$2995 | Single User
$5990 | Site License
$8985 | Enterprise License

Gene Therapies: A Diverse Range of Technologies with a Promising Long-Term Outlook
[Lowest Price Guaranteed: $2,995]

Published by CBR Pharma Insights: 01 Sep 2015 | 19901 | In Stock
Related Topics: Gene Therapy

Introduction

Gene Therapies: A Diverse Range of Technologies with a Promising Long-Term Outlook

Summary

GBI Research’s latest report, "Gene Therapies: A Diverse Range of Technologies with a Promising Long-Term Outlook" discusses all gene therapies under the broad criteria of genetic material introduced to the cell for a therapeutic purpose. It includes not only the insertion of a gene into the cell for expression, but also gene silencing with RNA interference (RNAi) and antisense RNA, aptamers (DNA or RNA polymers which bind to a protein target), and oncolytic viruses.

Gene therapies have been in development in humans for 25 years, and a number of products have begun to enter the pharmaceutical market. However, due to various challenges and clinical trial setbacks, progress in developing this technology and achieving suitability for commercial usage has been slow. Gene therapies only account for a marginal market share and many efficacy and safety concerns remain unaddressed. However, the pipeline is robust; 906 pipeline gene therapies are currently in development. Most are at an early stage of development, with 76% at the Discovery or Preclinical stage. However, there are currently 23 gene therapy programs in Phase III development and two at the Pre-registration stage. This indicates that although gene therapies are beginning to reach the market after two decades of research in humans, the majority remain in relatively early development.

This CBR report provides a comprehensive view of the clinical, R&D, commercial and competitive landscape of Gene Therapy, and assesses key developments in delivery vector technology, and challenges and advances associated with the production of such vectors.

Scope

Despite 25 years of clinical research, only a few gene therapies of all types have reached the market globally, and none have achieved strong clinical or commercial success -

- Why do gene therapies still occupy only a minimal market share in their respective indications?

- What can be learned from the gene therapies that have already reached the market?

A number of different viral and non-viral vector types are currently in development for the delivery of gene therapies -

- What are the relative advantages and disadvantages of each vector type and which hold the most promise?

- What proportion of the overall gene therapy R&D pipeline is occupied by each vector type?

The current pipeline for gene therapies is diverse in terms of the approaches and vectors covered; 50% are gene silencing therapies, while 31% involve the insertion of a functional gene -

- In which therapy areas is there the highest level of R&D activity for gene therapies?

- At which stage of development does the majority of pipeline gene therapies reside?

- What is the proportion of the pipeline occupied by each intervention and vector type overall?

A number of companies are currently actively developing pipeline gene therapies, including private, public and institutional enterprises -

- How do gene therapies fit into the overall portfolios of these companies?

- What is the level of involvement in gene therapy research from the top 20 Big Pharma companies?

Key Reasons to Purchase

This report will allow you to -

- Understand the current status of the field of therapeutic gene therapies, and the relative clinical and commercial success of currently marketed products, comprising Glybera, Kynamro, Macugen, Vitravene, Gendicine, Oncorine, and Neovasculgen.

- Assess the pipeline for gene therapies split by therapy area, vector type and intervention type, and stage of development. Additionally, a granular assessment of the pipeline is provided across the four major therapy areas for gene therapy: oncology, infectious diseases, central nervous system disorders, and genetic disorders.

- Gain a picture of the current competitive landscape, with a detailed breakdown of companies actively involved in the gene therapy pipeline. Understand the level of involvement on the part of big pharma companies, and the extent to which gene therapies fit into the overall portfolios of companies in this field. Additionally, a highly granular breakdown of companies developing multiple gene therapies is provided.

Table of Contents
for Gene Therapies: A Diverse Range of Technologies with a Promising Long-Term Outlook

  • Gene Therapy Overview

    Types of Gene Therapy

    Types of Intervention

    Types of Vector

    Currently Approved Gene Therapies

    Glybera (alipogene tiparvovec)

    Kynamro (mipomersen)

    Macugen (pegaptanib)

    Vitravene (fomivirsen)

    Gendicine (rAd-p53)

    Oncorine (rAd5-H101)

    Neovasculgen (Pl-VEGF165)

    Gene Therapy Production Strategies

    Production of Viral Vectors

    Case Study: Challenges in the Manufacture of AAV Vectors

    Challenges to Gene Therapy Development

    Gene Therapy Pipeline

    Gene Therapy Pipeline by Therapy Area and Stage of Development

    Gene Therapy Pipeline by Intervention and Vector Type

    Company Positioning

    Companies by Therapy Area

    Companies by Stage of Development

    Companies by Intervention Type

    Companies by Vector Type

    Conclusion

    Appendix

    References

    About GBI Research

Additional Details

Publisher

CBR Pharma Insights

Publisher Information

Reference

19901 |

Number of Pages

43

Report Format

PDF

CBR Pharma Insights Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Gene Therapy Partnering Terms and Agreements 2010 to 2016
The Global Gene Therapy Partnering Agreements 2010-2016 report provides an understanding and access ...
01 Oct 2016 by Current Partnering USD $2,995 More Info
Oxford Gene Technology Limited - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryOxford Gene Technology (OGT) is a biotechnology company that develops biomarkers. The company...
15 Mar 2016 by Global Data USD $250 More Info
Gene Techno Science Co., Ltd. (4584) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryGene Techno Science Co., Ltd. (GTS) is a biopharmaceutical company that develops and markets ...
10 Mar 2016 by Global Data USD $250 More Info
CRISPR/Cas 9 Gene Editing In Drug Discovery Trends 2016
HTStec's CRISPR/Cas 9 Gene Editing In Drug Discovery Trends 2016 report was published on 2 March 201...
02 Mar 2016 by HTStec USD $2,000 More Info
Oxford Gene Technology Limited - Medical Equipment - Deals and Alliances Profile
SummaryOxford Gene Technology (OGT) is a biotechnology company that develops biomarkers. The company...
25 Feb 2016 by Global Data USD $250 More Info
Da An Gene Co., Ltd. (002030) - Financial and Strategic SWOT Analysis Review
SummaryDa An Gene Co., Ltd. (Daan Gene) is a medical device company that offers molecular diagnostic...
09 Jan 2016 by Global Data USD $300 More Info
Da An Gene Co., Ltd. (002030) - Financial and Strategic SWOT Analysis Review
SummaryDa An Gene Co., Ltd. (Daan Gene) is a medical device company that offers molecular diagnostic...
08 Nov 2015 by Global Data USD $300 More Info
Oxford Gene Technology Limited - Medical Equipment - Deals and Alliances Profile
SummaryOxford Gene Technology (OGT) is a biotechnology company that develops biomarkers. The company...
23 Oct 2015 by Global Data USD $250 More Info
Physician Views: How comfortable are doctors with the commercial use of gene therapy?
Scope Gene therapy has been around for decades, yet in a sense the concept has recently been made to...
23 Mar 2015 by FirstWord Pharma USD $695 More Info
Physician Views: Are neurologists ready to embrace gene therapy?
Scope As recently noted by Forbes, the biotech bull market of 2013 has helped to revive an approach ...
11 Jun 2014 by FirstWord Pharma USD $695 More Info

This report is published by CBR Pharma Insights

Download Free Report Summary PDF

Gene Therapies: A Diverse Range of Technologies with a Promising Long-Term Outlook | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...